Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galac… Read more
Market Cap & Net Worth: Passage Bio Inc (PASG)
Passage Bio Inc (NASDAQ:PASG) has a market capitalization of $23.43 Million ($23.43 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25253 globally and #8640 in its home market, demonstrating a -16.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Passage Bio Inc's stock price $7.37 by its total outstanding shares 3178710 (3.18 Million).
Passage Bio Inc Market Cap History: 2020 to 2026
Passage Bio Inc's market capitalization history from 2020 to 2026. Data shows change from $81.28 Million to $23.43 Million (-16.66% CAGR).
Index Memberships
Passage Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #675 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2188 of 3165 |
Weight: Passage Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Passage Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Passage Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PASG by Market Capitalization
Companies near Passage Bio Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Passage Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Passage Bio Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Passage Bio Inc's market cap moved from $81.28 Million to $ 23.43 Million, with a yearly change of -16.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $23.43 Million | -37.54% |
| 2025 | $37.51 Million | +1980.76% |
| 2024 | $1.80 Million | -43.85% |
| 2023 | $3.21 Million | -26.81% |
| 2022 | $4.39 Million | -78.27% |
| 2021 | $20.18 Million | -75.17% |
| 2020 | $81.28 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Passage Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.43 Million USD |
| MoneyControl | $23.43 Million USD |
| MarketWatch | $23.43 Million USD |
| marketcap.company | $23.43 Million USD |
| Reuters | $23.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.